Market Overview

UPDATE: Goldman Sachs Downgrades Laboratory Corp. of America Holdings to Sell on Comparative Outlook

Share:
Related LH
Benzinga's Top Initiations
JMP Securities Initiates Laboratory of America With Market Outperform
MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook (Zacks)

Goldman Sachs reduced its rating on Laboratory Corp. of America Holdings (NYSE: LH) from Neutral to Sell with a $83 price target.

Goldman Sachs noted, "We downgrade LH shares to Sell from Neutral as we see better relative upside to the balance of our Tools and Diagnostics coverage universe. Our new 6-month price target of $83 (from $85) implies 1% upside (vs. 12% for the group on average). Our thesis is based on our view that (1) any volume upside driven from the Affordable Care Act (ACA) is likely to come at the cost of pricing and margins, (2) upside to consensus EPS will depend on an increasing amount of financial leverage, and (3) aggressive capital allocation is unlikely to drive significant multiple expansion."

Laboratory Corp. of America Holdings closed at $83.21 on Friday.

Latest Ratings for LH

DateFirmActionFromTo
Mar 2015JMP SecuritiesInitiates Coverage onMarket Outperform
Mar 2015Maxim GroupMaintainsBuy
Mar 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (LH)

Around the Web, We're Loving...